Modernizing Care of Patients With BCC: Changes in Management Approaches

Released On
January 19, 2022

Expires On
January 31, 2023

Media Type

Completion Time
90 minutes

Dermatology, Oncology


Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Evolve Medical Education, LLC (Evolve).

Supported by an unrestricted educational grant from Regeneron Pharmaceuticals.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

MDs, PAs, and NPs in Dermatology and Oncology

Program Overview

Utilize an interdisciplinary approach to identify patients with advanced BCC and apply expert guidance and clinical guidelines to determine the best treatment pathway for individual patients.

Identify patients with advanced BCC who have failed or cannot tolerate hedgehog inhibitor therapy and utilize an interdisciplinary approach to assess treatment options, including PD-1 inhibitors, and develop a plan to prevent/manage treatment-associated adverse events.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients for whom hedgehog inhibitor therapy may no longer be viable due to lack of response or adverse events
  • Apply expert guidance to augment guideline recommendations when determining treatment pathways in patients with advanced BCC
  • Summarize pivotal data on the efficacy and safety of PD-1 inhibitors, and their practical implications for treatment selection and AE prevention and management
  • Design an interdisciplinary approach to identifying patients with advanced BCC
  • Identify non-clinical patient needs to consider when assembling an interdisciplinary team to direct treatment and manage patients with advanced BCC




Anthony M. Rossi, MD, FAAD

Dermatologic, Mohs, & Laser Surgery
Assistant Professor
Weill Cornell Medical College
Assistant Attending
New York Presbyterian Hospital
Memorial Sloan Kettering Cancer Center
New York, New York


Vernon K. Sondak, MD

Chair, Department of Cutaneous Oncology
Moffitt Cancer Center
Richard M. Schulze Family Foundation Distinguished Endowed Chair in Cutaneous Oncology
Professor, Departments of Oncologic Sciences and Surgery
USF Morsani College of Medicine
Tampa, Florida

Accreditation Statement

Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Designation Statement

Evolve designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistant Continuing Education

PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosures of Conflicts of Interest

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

The following faculty/staff members have the following financial relationships with ineligible companies.

Anthony M. Rossi, MD, FAAD, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Allergan. Consultant: Almirall, Biofrontera, Canfield Scientific, Dynamed, Evolus, Lam Therapeutics, Merz, Quantia MD, and Regeneron Pharmaceuticals. Grant/Research Support: Biofrontera, Leo Pharma, and Regeneron Pharmaceuticals. Speaker’s Bureau: Almirall, and Biofrontera.

Vernon K. Sondak, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: BMS, Eisai, Merck, Novartis, Regeneron Pharmaceuticals, and Replimune. Grant/Research: Neogene Therapeutics.

The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
Recommended internet speed 5Mbps+

Off-Label Statement

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals.